A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

Clinical Transplantation

Volumn 22, Issue 2, 2008, Pages 200-210

  Ciancio, Gaetano ^a   Burke, George W ^a   Gaynor, Jeffrey J ^a   Roth, David ^b   Kupin, Warren ^b   Rosen, Anne ^a   Cordovilla, Tatiana ^a   Tueros, Lissett ^a   Herrada, Eva ^a   Miller, Joshua ^a,c  

^a Florida   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

African Americans; Alemtuzumab; Campath 1H; Daclizumab; Hispanics; Mycophenolate mofetil; Tacrolimus; Thymoglobulin

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; COTRIMOXAZOLE; DACLIZUMAB; GANCICLOVIR; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISPANIC AMERICANS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 41049115598     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00774.x     Document Type: Article

References (25)

1. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998: 338: 161.
2. Kahan BD, Rajagopalan PR, Hall M, for the United States Simulet Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999: 67: 276.
3. Ciancio G, Burke GW, Suzart K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002: 73: 1100.
4. Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplant. Transplantation 1998: 66: 29.
5. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003: 76: 798.
6. Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004: 240: 510.
7. Knechtle SJ, Pirsch JD, Fechner HJ Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003: 3: 722.
8. Ciancio G, Burke GW, Gaynor JJ et al. The use of campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004: 78: 426.
9. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998: 351: 1701.
10. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005: 80: 457.
11. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004: 77: 244.
12. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1year. Transplantation 2004: 77: 252.
13. Burke GW, Ciancio G, Mattiazzi A, Gomez C, Rosen A, Miller J. Can acute rejection be prevented in SPK transplantation? A randomized, prospective study with thymoglobulin/zenapax induction, tacrolimus and steroid maintenance: Comparing rapamycin with mycophenolate mofetil. Am J Transplant 2004: 4: 562.
14. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
15. C ockcroft DW, G ault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
16. ter Meulen CG, van Riemsdijk I, Hené RJ et al. Steroid-withdrawal at 3days after renal transplantation with anti-IL-2 receptor alpha therapy: A prospective, randomized, multicenter study. Am J Transplant 2004: 4: 803.
17. K hwaja K, A solati M, H armon J et al. Outcome at 3years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients. Am J Transplant 2004: 4: 980.
18. S inclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992: 147: 645.
19. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996: 348: 643.
20. Sanchez-Fructuoso AI, Marques M, Conesa J et al. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors. Transplant Int 2005: 18: 596.
21. Gourishankar S, Halloran PF. Late deterioration of organ transplants: A problem in injury and homeostasis. Curr Opin Immunol 2002: 14: 576.
22. Waaga AM, Gasser M, Laskowski I, Tilney NL. Mechanisms of chronic rejection. Curr Opin Immunol 2000: 12: 517.
23. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, Tilney NL. Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplant 2000: 5: 29.
24. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997: 63: 977.
25. Mc Cune TR, Thacker LR II, Peters TG et.al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998: 65: 87.